» Articles » PMID: 8709403

Elevated Plasma Lipoprotein(a) and Coronary Heart Disease in Men Aged 55 Years and Younger. A Prospective Study

Overview
Journal JAMA
Specialty General Medicine
Date 1996 Aug 21
PMID 8709403
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To establish whether elevated lipoprotein(a) [Lp(a)], detected as a sinking pre-beta-lipoprotein band on electrophoresis of fresh plasma, is an independent risk factor for the development of premature coronary heart disease (CHD) in men.

Design And Setting: Prospective study of the Framingham offspring cohort.

Participants: A total of 2191 men aged 20 to 54 years old who were free of cardiovascular disease when they were examined between 1971 and 1975.

Main Outcome Measures: Incident CHD (myocardial infarction, coronary insufficiency, angina pectoris, or sudden cardiac death) occurring by age 55 years.

Results: After a median follow-up of 15.4 years, there were 129 CHD events. The relative risk (RR) estimates (with 95% confidence intervals [CIs]) for premature CHD derived from a proportional hazards model that included age, body mass index, and the dichotomized risk factor covariables elevated plasma Lp(a) level, total cholesterol level of 6.2 mmol/L (240 mg/dL) or more, high-density lipoprotein (HDL) level less than 0.9 mmol/L (35 mg/dL), smoking, glucose intolerance, and hypertension were as follows: elevated Lp(a) level, RR, 1.9 (95% CI, 1.2-2.9), prevalence, 11.3%; total cholesterol level of 6.2 mmol/L or more, RR, 1.8 (95% CI, 1.2-2.7), prevalence, 14.3%; HDL level of less than 0.9 mmol/L, RR, 1.8 (95% CI, 1.2-2.6), prevalence 19.2%; smoking, RR 3.6 (95% CI, 2.2-5.5), prevalence, 46.7%; glucose intolerance, RR, 2.7 (95% CI, 1.4-5.3), prevalence, 2.6%; hypertension, RR, 1.2 (95% CI, 0.8-1.8), prevalence, 26.3%.

Conclusions: Elevated plasma Lp(a) is an independent risk factor for the development of premature CHD in men, comparable in magnitude and prevalence (ie, attributable risk) to a total cholesterol level of 6.2 mmol/L (240 mg/dL) or more, or an HDL level less than 0.9 mmol/L (35 mg/dL).

Citing Articles

Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.

Nicholls S, Ni W, Rhodes G, Nissen S, Navar A, Michael L JAMA. 2024; 333(3):222-231.

PMID: 39556768 PMC: 11574718. DOI: 10.1001/jama.2024.24017.


Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening.

Khan T, Bragazzi Cunha J, Raut C, Burroughs M, Goonewardena S, Smrcka A bioRxiv. 2024; .

PMID: 38766193 PMC: 11100788. DOI: 10.1101/2024.05.11.593568.


Development of a Modified Friedewald's Formula to Calculate Low-Density Lipoprotein in an Iranian Population.

Sobhani S, Kheirandish M, Rafati S, Rafat M, Shahbazi R, Azarbad A Iran J Med Sci. 2023; 48(5):484-492.

PMID: 37786463 PMC: 10541546. DOI: 10.30476/IJMS.2022.95469.2683.


The Development of Dyslipidemia in Chronic Kidney Disease and Associated Cardiovascular Damage, and the Protective Effects of Curcuminoids.

Ceja-Galicia Z, Aranda-Rivera A, Amador-Martinez I, Aparicio-Trejo O, Tapia E, Trujillo J Foods. 2023; 12(5).

PMID: 36900438 PMC: 10000737. DOI: 10.3390/foods12050921.


Correlation of lipoprotein (a) levels and plaque morphology in very young acute coronary syndrome patients using optical coherence tomography.

Chandra S, Nagar S, Shukla A, Chaudhary G, Sharma A, Pradhan A Indian Heart J. 2022; 74(5):357-362.

PMID: 36349584 PMC: 9647656. DOI: 10.1016/j.ihj.2022.09.001.